Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $150.00. The company’s shares closed yesterday at $121.78.
According to TipRanks, O’Brien is a 5-star analyst with an average return of 7.1% and a 53.07% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Boston Scientific, Dexcom, and Sight Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $150.62 average price target, representing a 23.68% upside. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $150.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $139.55 and a one-year low of $74.75. Currently, Dexcom has an average volume of 2.95M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dexcom (DXCM) Company Description:
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
Read More on DXCM:
- DexCom’s (NASDAQ:DXCM) Stelo Becomes the First Glucose Monitor to be Cleared for OTC Use
- DexCom announces new CGM data, direct to Apple Watch functionality in Q2
- DexCom call volume above normal and directionally bullish
- Dexcom Finalizes Stock Warrant Termination and Equity Deals
- Coleman’s Tiger Global bought Broadcom and DexCom during Q4
